Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GSK wins FDA full approval for ITP treatment Promacta
GSK said the oral tablet Promacta can raise platelet counts in patients with the rare blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient
GSK said the oral tablet Promacta can raise platelet counts in patients with the rare blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient
The milestone was paid pursuant to the previously announced sale to Cowen Royalty of Aeterna Zentaris‘ rights to royalties on future net sales of Cetrotide, covered by the
Ipsen and bioMerieux have decides to co identify programs that would benefit from the co-development of a therapeutic and a companion diagnostic test, notably in the prevention and
Elan filed the patent litigation case against Abraxis BioScience in 2006, which was acquired by Celgene in October 2010. In consideration of the terms of the settlement and
Shields recently worked as a CEO of Artromick International, a developer of healthcare technology for acute and long-term care markets. Prior to Artromick, he was senior vice president
The study will focus initially on the safety and tolerability of IQNLF, one component of IQ-DAA. The study is being conducted by QPS Netherlands BV, and will initially
Omnicare offers clinical research services for the pharmaceutical and biotechnology industries. The company reported net loss was $65.29m, compared to a net income of $79.79m for the same
The two companies will provide over 10,000 cancer care professionals with early access to the latest panels of protein biomarkers implicated in different cancers. Avantra had announced the
Persistent’s PaxPro Brand Asset Lifecycle Management solution is a secure, policy-based solution designed to review and approve all media content within complex packaging and branding workflows. It offers
Modufolin is anticipated to increase the efficacy and reduce the side effects of cytotoxic pharmaceuticals. The approval allows Isofol Medical to start its first clinical trial on humans,